January 2014, Parsippany, NJ, USA – Diagnostica Stago Inc. announces launch of STA® – Apixaban Calibrator and Controls for use with the STA® - Liquid Anti-Xa assay (catalog #s 00311US and 00322US). The bar-coded, automation-ready calibrators and controls expand the utility of STA® - Liquid Anti-Xa for specific measurement of apixaban activity in plasma for research purposes. The chromogenic STA® - Liquid Anti-Xa with STA® – Apixaban Calibrator and Controls has demonstrated excellent analytical performance with respect to sensitivity, dynamic range of the assay, inter-subject variability and coefficient of variation (CV).1,2,3
Apixaban (Eliquis®) is an oral, twice daily, anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. A selective active site inhibitor of coagulation factor Xa, apixaban inhibits the blood coagulation cascade by blocking the action of coagulation factor Xa, independent of antithrombin III, resulting in inhibition of fibrin clot formation.2
STA®–Apixaban Calibrator (catalog # 01112) contains four (4) levels of calibrator, to establish a wide linear working range from 20 ng/mL to 500 ng/mL. In addition, the STA®–Apixaban Control (catalog # 01111) contains two (2) levels of control one each for the low and high ends of the linear range. The calibrator is stable for 4 hours and the control for a full 8-hour shift on board the STA line of automated coagulation analyzers. In addition, the reconstituted control is stable at 2-8° C for 7 days to facilitate flexible testing schedules.
Utilization of STA®–Apixaban Calibrator and Controls ensures high specificity and precision for measurement of apixaban activity. In addition, barcoding of critical information on the reagent vials supports automated reagent management and prevents transcription errors.
STA®–Apixaban Calibrator and Controls are labeled for research use only, and are not for use in diagnostic procedures in the United States or Canada.
1. Becker RC et al., Chromogenic laboratory assays to measure the factor-Xa inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183-187
2. Barret YC et al., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271
3. Barret YC et al., A randomized assessment of the pharmacokinetic, pharmacodynamic, and safety intereaction between apixaband and enoxaparin in healthy subjects. Thromb Haemost 2012; 107: 916=92
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.
ELIQUIS is a registered trademark of Bristol-Myers Squibb Company.